The federal government has announced over $40 million from the Biomedical Translation Fund for a number of Australian biotechnology companies.

Monash University has a new project that aims to use a range of new technologies to help address one of the world's most serious health issues, antimicrobial resistance.

Immutep (ASX:IMM) has announced the completion of a $29.6 million share placement to professional, institutional and sophisticated investors, and an expanded collaboration with MSD.

During World Antimicrobial Awareness Week, AusBiotech celebrates the leading work of the Australian life sciences industry as it prepares for the role it may take in addressing antimicrobial resistance, and the opportunities and barriers ahead of us.

Research Australia is seeking input on a new survey on the impact of COVID-19 on health and medical research and innovation.

GSK Australia has joined MTPConnect's REDI initiative to support a PhD graduate program that is designed to facilitate closer collaboration between researchers and the biopharmaceutical industry.

QBiotics Group, a life sciences company developing novel anti-cancer and wound healing therapies, has announced the US FDA's Center for Veterinary Medicine (CVM) has approved its STELFONTA.

CSL and the federal government have announced a $1.8 billion deal under which the Australian company will construct a new manufacturing facility in return for a flu vaccine and other product supply commitment.

The Clinical Trial Exemption (CTX) scheme - one of the two avenues available for trials of unapproved therapeutic goods in Australia - has been renamed as the Clinical Trial Approval (CTA) scheme.